Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7332578 | 0.78 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL188509 | 0.77 | TAAR1 (0.57) | CA1CA2CA7CA9CA12 | |
| SCHEMBL7038288 | 0.76 | CA12 (0.49) | CA1CA2CA12CA14SMN1; SMN2 | |
| SCHEMBL2096467 | 0.75 | CA1 (0.41) | CA1CA2CA7CA9CA12 | |
| SCHEMBL1044930 | 0.75 | CA1 (0.50) | CA1CA2CA7CA9CA12 | |
| SCHEMBL5250993 | 0.74 | CA2 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL5544191 | 0.74 | HIF1A (0.45) | CA1CA2CA7CA9CA12 | |
| SCHEMBL1205557 | 0.74 | CA12 (0.39) | CA1CA2CA7CA9CA12 | |
| SCHEMBL15155367 | 0.74 | CA12 (0.39) | CA1CA2CA7CA9CA12 | |
| SCHEMBL5062127 | 0.72 | KDM4E (0.39) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107001390-A | Boronic acid derivatives | 默克专利股份公司 | 2017-08-01 | — | — | CN | claimed |
| CN-107001390-A | Boronic acid derivatives | 默克专利股份公司 | 2017-08-01 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-5532353-A | Process for the preparation of halogenated β-lactam compounds | BIOCHIMICA OPOS SPA (IT) | 1996-07-02 | — | — | US | disclosed |
| EP-0570058-A2 | Process for the preparation of halogenated beta-lactam compounds | BIOCHIMICA OPOS SPA (IT) | 1993-11-18 | — | — | EP | disclosed |
| US-4560749-A | ANTIBIOTICS, BACTERICIDES | ELI LILLY AND COMPANY (US) | 1985-12-24 | — | — | US | disclosed |
| US-4208515-A | 3-Halo cephalosporins | ELI LILLY AND COMPANY (US) | 1980-06-17 | — | — | US | disclosed |
| US-4065618-A | Process for 3-H-3-cephem esters | ELI LILLY AND COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4065621-A | Process for 3-alkyl and 3-phenyl cephalosporins | ELI LILLY AND COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4064343-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1977-12-20 | — | — | US | disclosed |
| US-4042472-A | Electrolytic process for 7-methoxy-3-exomethylenecepham compounds | ELI LILLY AND COMPANY (US) | 1977-08-16 | — | — | US | disclosed |
| US-4013651-A | 3-SUBSTITUTED AMINO-CEPHALOSPORINS | ELI LILLY AND COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
| US-3992377-A | 3-Thio-substituted cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
| US-3985737-A | ANTIBACTERIAL AGENTS | ELI LILLY AND COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3976635-A | Novel esterifying agents, and their production and use | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-08-24 | — | — | US | disclosed |
| US-3962227-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CA1 3493/4885CA2 1853/4885CA7 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.